[go: up one dir, main page]

PE20110065A1 - Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8 - Google Patents

Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8

Info

Publication number
PE20110065A1
PE20110065A1 PE2010000421A PE2010000421A PE20110065A1 PE 20110065 A1 PE20110065 A1 PE 20110065A1 PE 2010000421 A PE2010000421 A PE 2010000421A PE 2010000421 A PE2010000421 A PE 2010000421A PE 20110065 A1 PE20110065 A1 PE 20110065A1
Authority
PE
Peru
Prior art keywords
compositions
polysaccharide
staphylococcus aureus
methods
capsular polysaccharide
Prior art date
Application number
PE2010000421A
Other languages
English (en)
Inventor
Stephen John Freese
Annaliesa Anderson
Viliam Pavliak
Jansen Kathrin Ute
Dodge Ingrid Lea
Scott Tracy Dee
Nanra Jasdeep Singh
A Krishna Prasad
Bruce Arthur Green
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PE20110065A1 publication Critical patent/PE20110065A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN CONJUGADO INMUNOGENICO DE POLISACARIDO-PROTEINA QUE COMPRENDE UN POLISACARIDO CAPSULAR DE SEROTIPO 8 O 5 DE STAPHYLOCOCCUS AUREUS AISLADO CONJUGADO A UNA PROTEINA PORTADORA, DONDE EL POLISACARIDO TIENE UN PESO MOLECULAR DE ENTRE 20 KDa Y 1000 KDa Y LA PROTEINA PORTADORA ES CRM197, LA CUAL ESTA LIGADA COVALENTEMENTE AL POLISACARIDO MEDIANTE UN ENLACE DE CARBAMATO, UN ENLACE AMIDA O AMBOS. ASIMISMO, LA PROTEINA CMR197 COMPRENDE DE 8 A 15 LISINAS ENLAZADAS COVALENTEMENTE AL POLISACARIDO. TAMBIEN ESTA REFERIDA A UNA COMPOSICION INMUNOGENICA Y A UN METODO DE PREPARACION
PE2010000421A 2009-06-22 2010-06-22 Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8 PE20110065A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21914309P 2009-06-22 2009-06-22
US21915109P 2009-06-22 2009-06-22

Publications (1)

Publication Number Publication Date
PE20110065A1 true PE20110065A1 (es) 2011-01-31

Family

ID=43599164

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010000421A PE20110065A1 (es) 2009-06-22 2010-06-22 Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8

Country Status (22)

Country Link
US (2) US9125951B2 (es)
EP (2) EP3461496B1 (es)
JP (4) JP2012530785A (es)
KR (2) KR20140119165A (es)
CN (1) CN102625713A (es)
AR (1) AR077190A1 (es)
AU (1) AU2010301043B2 (es)
BR (1) BRPI1011753B8 (es)
CA (1) CA2766418C (es)
CO (1) CO6480930A2 (es)
ES (2) ES2959890T3 (es)
IL (1) IL217085B (es)
MX (1) MX2012000045A (es)
MY (1) MY158231A (es)
NZ (1) NZ597191A (es)
PE (1) PE20110065A1 (es)
PH (2) PH12015502508A1 (es)
RU (1) RU2531234C2 (es)
SA (1) SA114350400B1 (es)
SG (2) SG177310A1 (es)
TW (2) TW201544119A (es)
WO (1) WO2011041003A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2445522T3 (pl) 2009-06-22 2018-01-31 Wyeth Llc Kompozycje immunogenne antygenów Staphylococcus aureus
US8974799B2 (en) * 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
SI2493498T1 (sl) 2009-10-30 2017-07-31 Glaxosmithkline Biologicals Sa Čiščenje kapsularnih saharidov Staphylococcusa aureusa tipa 5 in tipa 8
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
PL3421051T3 (pl) 2012-08-16 2020-10-05 Pfizer Inc. Sposoby glikokoniugacji i kompozycje
KR102118071B1 (ko) 2012-11-21 2020-06-02 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 박테리아 다당류를 고수율로 제조하는 방법
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
EP3096786B1 (en) * 2014-01-21 2021-07-07 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
EP3142684A4 (en) 2014-05-12 2018-05-23 Purdue Research Foundation Selectin and icam/vcam peptide ligand conjugates
CA2956188A1 (en) * 2014-08-08 2016-02-11 Glycovaxyn Ag Modified host cells for use in bioconjugate production
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
NZ736238A (en) * 2015-05-04 2022-07-01 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CN108367063A (zh) * 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
US10946085B2 (en) * 2016-02-15 2021-03-16 Hipra Scientific, S.L.U. Streptococcus uberis extract as an immunogenic agent
WO2017158480A1 (en) * 2016-03-15 2017-09-21 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel polysaccharide-protein conjugates and process to obtain thereof
WO2019050818A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. METHODS OF FORMULATING PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
KR20240011879A (ko) * 2017-02-24 2024-01-26 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진
JP7218358B2 (ja) 2017-09-07 2023-02-06 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
WO2019212844A1 (en) * 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
WO2019212846A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
AU2021224078B2 (en) 2020-02-21 2024-01-18 Pfizer Inc. Purification of saccharides
CN111228478A (zh) * 2020-02-25 2020-06-05 江南大学 三糖重复单元寡糖链在制备金黄色葡萄球菌疫苗中的应用
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
JP2024521847A (ja) * 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US150688A (en) 1874-05-12 Improvement in centrifugal machines
US4134214A (en) 1977-08-05 1979-01-16 Merck & Co., Inc. Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
IL78775A (en) 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CA2047031A1 (en) 1990-07-19 1992-01-20 Stephen Marburg Peptide-polysaccharide-protein conjugate vaccines
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
AU681573B2 (en) 1991-11-22 1997-09-04 Glaxosmithkline Biologicals Sa Type I and type II surface antigens associated with (staphylococcus epidermidis)
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
EP0616034B1 (en) 1993-03-05 2004-10-20 Wyeth Holdings Corporation Plasmid for production of CRM protein and diphtheria toxin
AU678613B2 (en) 1993-09-22 1997-06-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996014873A2 (en) * 1994-11-16 1996-05-23 Sri International COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
IL121585A0 (en) * 1995-06-07 1998-02-08 Alberta Res Council Immunogenic and immunostimulatory oligosaccharide compositions and methods of preparing and using them
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
AU8070898A (en) 1997-06-12 1998-12-30 Shin-Etsu Bio, Inc. Production of non-native bacterial exopolysaccharide in a recombinant bacteri al host
WO1999003871A1 (en) 1997-07-17 1999-01-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hexadecasaccharide-protein conjugate vaccine for shigella dysenteriae type 1
JP4486748B2 (ja) 1997-11-26 2010-06-23 インヒビテツクス，インコーポレイテツド 黄色ブドウ球菌由来の細胞外マトリックス結合タンパク質
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
IL141639A (en) 1998-08-31 2005-12-18 Inhibitex Inc Multicomponent vaccines
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
MY125202A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
JP2004501869A (ja) 2000-03-22 2004-01-22 ソルリンク・インコーポレイテッド ヒドラジンベース及びカルボニルベースの二官能性架橋剤
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
SI1296713T1 (en) 2000-06-08 2004-02-29 Intercell Biomedizinische Forschungs- Immunostimulatory oligodeoxynucleotides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
JP2005506047A (ja) * 2001-03-27 2005-03-03 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー 膜貫通型セリンプロテアーゼ９をコード化する核酸分子、コード化されたポリペプチドおよびそれらに基づく方法
CN1541111A (zh) 2001-06-07 2004-10-27 ���Ͽع����޹�˾ 作为佐剂的霍乱全毒素的突变形式
DE60234695D1 (de) 2001-06-07 2010-01-21 Univ Colorado Mutantenformen von cholera holotoxin als adjuvans
CA2351018A1 (en) 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
FR2828404B1 (fr) 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US20030092062A1 (en) * 2001-10-24 2003-05-15 Reddy M. Parameswara Immobilizing biological molecules
BR0308768A (pt) * 2002-03-26 2005-02-15 Chiron Srl Sacarìdeos modificados possuindo estabilidade melhorada em água
TW200306314A (en) 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
AU2003295520B8 (en) 2002-11-12 2011-05-19 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for Staphylococcal infections
JP4078417B2 (ja) 2003-03-04 2008-04-23 独立行政法人産業技術総合研究所 好熱菌由来オリゴペプチダーゼ
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
US7887789B2 (en) * 2003-05-23 2011-02-15 Nektar Therapeutics Polymer derivatives having particular atom arrangements
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
HUE026000T2 (en) 2003-12-17 2016-04-28 Wyeth Llc Immunogenic peptide-bearing conjugates and methods for their preparation
US7537766B2 (en) 2004-08-30 2009-05-26 Wyeth Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
MX2007003402A (es) * 2004-09-22 2007-05-10 Glaxosmithkline Biolog Sa Composicion inmunogena para su uso en vacunacion contra estafilococos.
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
WO2007000341A2 (en) * 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
PH12013500136A1 (en) 2006-03-30 2015-03-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
FR2899110A1 (fr) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
ES2677353T3 (es) 2007-03-23 2018-08-01 Wyeth Llc Procedimiento abreviado de purificación para la producción de polisacáridos capsulares de Streptococcus pneumoniae
EP2589392B1 (en) 2008-03-05 2016-11-30 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
PL2445522T3 (pl) * 2009-06-22 2018-01-31 Wyeth Llc Kompozycje immunogenne antygenów Staphylococcus aureus
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
SI2493498T1 (sl) 2009-10-30 2017-07-31 Glaxosmithkline Biologicals Sa Čiščenje kapsularnih saharidov Staphylococcusa aureusa tipa 5 in tipa 8
PL2654784T3 (pl) 2010-12-22 2017-08-31 Wyeth Llc Stabilne immunogenne kompozycje antygenów staphylococcus aureus

Also Published As

Publication number Publication date
TW201544119A (zh) 2015-12-01
KR20120048568A (ko) 2012-05-15
JP2016053051A (ja) 2016-04-14
KR20140119165A (ko) 2014-10-08
IL217085B (en) 2018-10-31
RU2011152045A (ru) 2013-07-27
ES2729934T3 (es) 2019-11-07
CA2766418A1 (en) 2011-04-07
AU2010301043B2 (en) 2014-01-09
SA114350400B1 (ar) 2016-05-26
EP3461496A1 (en) 2019-04-03
US20160022798A1 (en) 2016-01-28
CN102625713A (zh) 2012-08-01
KR101774062B1 (ko) 2017-09-01
JP2017179378A (ja) 2017-10-05
JP6153581B2 (ja) 2017-06-28
ES2959890T3 (es) 2024-02-28
JP6393804B2 (ja) 2018-09-19
AR077190A1 (es) 2011-08-10
SG177310A1 (en) 2012-02-28
PH12015502508A1 (en) 2019-06-03
US9623100B2 (en) 2017-04-18
SG10201406432RA (en) 2014-11-27
PH12021551159A1 (en) 2022-02-21
BRPI1011753A2 (pt) 2016-03-29
WO2011041003A3 (en) 2011-10-27
US20120276137A1 (en) 2012-11-01
WO2011041003A9 (en) 2011-06-09
NZ597191A (en) 2013-11-29
EP2445523B1 (en) 2019-04-17
EP3461496B1 (en) 2023-08-23
EP2445523A2 (en) 2012-05-02
US9125951B2 (en) 2015-09-08
MY158231A (en) 2016-09-15
BRPI1011753B8 (pt) 2021-05-25
BRPI1011753B1 (pt) 2021-03-02
JP2013237693A (ja) 2013-11-28
CA2766418C (en) 2016-03-29
CO6480930A2 (es) 2012-07-16
IL217085A0 (en) 2012-02-29
WO2011041003A2 (en) 2011-04-07
AU2010301043A1 (en) 2012-01-19
TW201110977A (en) 2011-04-01
RU2531234C2 (ru) 2014-10-20
JP2012530785A (ja) 2012-12-06
TWI505834B (zh) 2015-11-01
MX2012000045A (es) 2012-01-30

Similar Documents

Publication Publication Date Title
PE20110065A1 (es) Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
AR116043A2 (es) Composición de vacuna conjugada de polisacárido-proteína neumocócica 15-valente
AR084158A1 (es) Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
ZA201901170B (en) Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
AR060187A1 (es) Composicion inmunogenica
BR112020004509A8 (pt) Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
PE20071058A1 (es) Vacuna de streptococcus pneumoniae
BR112020004471A8 (pt) Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
MX337528B (es) Composición inmunogénica que comprende un sacárido capsular estafilocócico o-acetilado y una proteína estafilocócica.
FI3583947T3 (fi) Streptococcus pneumoniaen kapselipolysakkaridit ja niiden konjugaatit
CL2007003781A1 (es) Metodo para la elaboracion de un conjugado inmunogenico que comprende el polisacarido del serotipo 1 de streptococcus pneumoniae covalentemente unido a una proteina vehiculo; y proceso para preparar una composicion inmunogenica multivalente polisacarido-proteina.
BRPI0519232A2 (pt) vacinas de conjugados de sacarÍdeos
AR092897A1 (es) Composiciones inmunogenicas
ZA202310611B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ZA202103560B (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine
CL2012000744A1 (es) Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende.
BRPI0915517B8 (pt) método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica
PE20080774A1 (es) Composicion inmunogenica que comprende pnag de estafilococos conjugada con una proteina portadora y polisacarido u oligosacarido capsular de s. aureus
MX2013002841A (es) Composiciones inmunogenas.
AR093161A1 (es) Composicion de conjugados polisacarido-proteina neumococicos multivalente

Legal Events

Date Code Title Description
FG Grant, registration